INVA Innoviva Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INVA

Price (delayed)

$21.795

Market cap

$1.61B

P/E Ratio

3.03

Dividend/share

N/A

EPS

$7.2

Enterprise value

$1.26B

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 37
Relative Valuation: Rel. Valuation: 97
Relative Profitability: Rel. Profitability: 99

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic ...

Highlights
The equity has surged by 107% year-on-year and by 14% since the previous quarter
INVA's net income has surged by 86% since the previous quarter
Innoviva's gross margin has decreased by 12% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inva.com
Peers: OPK ORGO

Key stats

What are the main financial stats of INVA

INVA stock price

How has the Innoviva stock price performed over time
Intraday
6.27%
1 week
2.71%
1 month
-0.11%
1 year
19.42%
YTD
9.03%
QTD
-4.03%

Financial performance

How have Innoviva's revenue and profit performed over time
Revenue
$420.69M
Gross profit
$310.19M
Operating income
$160.47M
Net income
$504.34M
Gross margin
73.7%
Net margin
119.9%
INVA's net income has surged by 86% since the previous quarter
The net margin has soared by 82% from the previous quarter
The operating margin has decreased by 23% YoY and by 4.3% from the previous quarter
The revenue has grown by 14% YoY and by 2.3% from the previous quarter

Price vs fundamentals

How does INVA's price correlate with its fundamentals

Growth

What is Innoviva's growth rate over time

Valuation

What is Innoviva stock price valuation
INVA P/E details
P/E
3.03
P/B
1.2
P/S
3.84
EV/EBIT
2.05
EV/EBITDA
1.92
EV/Sales
3
The company's EPS has surged by 79% QoQ
The stock's price to earnings (P/E) is 78% less than its last 4 quarters average of 12.7 and 73% less than its 5-year quarterly average of 10.7
The equity has surged by 107% year-on-year and by 14% since the previous quarter
The P/B is 37% below the 5-year quarterly average of 1.8 and 19% below the last 4 quarters average of 1.4
The P/S is 17% higher than the 5-year quarterly average of 3.1 and 3.4% higher than the last 4 quarters average of 3.5
The revenue has grown by 14% YoY and by 2.3% from the previous quarter

Efficiency

How efficient is Innoviva business performance
The company's return on sales has surged by 76% QoQ
INVA's ROA has soared by 69% from the previous quarter
The return on invested capital has surged by 66% since the previous quarter
INVA's return on equity has surged by 56% since the previous quarter

Dividends

What is INVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Innoviva financials performed over time
The total assets rose by 46% year-on-year and by 12% since the previous quarter
Innoviva's quick ratio has increased by 45% from the previous quarter
The debt is 81% less than the equity
The equity has surged by 107% year-on-year and by 14% since the previous quarter
The debt to equity has dropped by 72% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.